BLRXBioLineRx, Ltd.
$3.31
$0.10
(2.88%)
Closed $3.37
$0.06
(1.78%)
After Hours
Reported EarningsMay 27
Mkt Cap$14.72M
Vol51,292.00
Fundamentals
Mkt Cap
$14.72M
Volume
-
52W High
$5.06
52W Low
$2.15
PE Ratio
-1.57
Avg. Volume
110,838.81
EPS (Annual)
-$0.2903
Rev/Employee
$49,556.71
Earnings
May 27
59
Bullish Sentiment
How do you feel about BLRX?
BioLineRx (BLRX) Q1 2026 Earnings Transcript
@media (max-width: 768px) {
.image-container {
width: 100% !important;
float: none !important;
margin: 0 0 1rem 0 !important;
}
}
Image source: The Mo...
Nasdaq News: Markets
BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update
BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update PR Newswire TEL AVIV, Israel, May 27, 2026 - Announced first patient dosed in Phase 1/2a clinical trial of GLIX1 for treatment of...
PR Newswire
BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting PR Newswire TEL AVIV, Israel and OSLO...
PR Newswire
BioLineRx to Report First Quarter 2026 Results on May 27, 2026
BioLineRx to Report First Quarter 2026 Results on May 27, 2026 BioLineRx to Report First Quarter 2026 Results on May 27, 2026 PR Newswire TEL AVIV, Israel, May 20, 2026 Management to Hold Conference Call at 8:30 a.m. EDTTEL AVIV, Israel, May 20, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX...
PR Newswire
BioLineRx Drug Shows Anti-Tumor Activity In Brain Tumor Animal Models
BioLineRx shares new GLIX1 glioblastoma data showing anti-tumor activity, including in temozolomide-resistant cancer models.read more...
Benzinga
BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts
BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with...
PR Newswire
BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a...
PR Newswire
BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM...
PR Newswire
BioLineRx Reports 2025 Financial Results and Provides Corporate Update
BioLineRx Reports 2025 Financial Results and Provides Corporate Update BioLineRx Reports 2025 Financial Results and Provides Corporate Update PR Newswire TEL AVIV, Israel, March 23, 2026 - On track...
PR Newswire
<
1
2
...
>
Advertisement|Remove ads.
Latest BLRX News
ViewBioLineRx (BLRX) Q1 2026 Earnings Transcript
Nasdaq News: Markets
BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update
PR Newswire
BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
PR Newswire
Advertisement|Remove ads.